3 min read
Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development
Geneva, Switzerland, November 1, 2021 – Selexis SA, a JSR Life Sciences company, today announced that business and...
Geneva, Switzerland, November 1, 2021 – Selexis SA, a JSR Life Sciences company, today announced that business and...
Geneva, Switzerland, and Durham, NC – June 29, 2021 – Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences...
Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of...
Geneva, Switzerland, May 27, 2021 – Selexis SA, a JSR Life Sciences company, announced today that Great Place to Work® ...
Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service...
Geneva, Switzerland, March 18, 2021 – Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company...
Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and...
Geneva, Switzerland, and Boston, Mass., March 9, 2021 – Selexis SA and Boston Immune Technologies and Therapeutics...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.